Southern Biotech Center Opens New Office with Support from NVIDIA and AMD Researchers
25 March 2025 路 Uncategorized 路
The Bio-Technology Development Center has announced the establishment of its 'Biotech Southern Office.' Chairman Tu Hsing-Chieh stated that, while previously focusing on northern Taiwan, the center now aims to bring technology southward for integration with local resources and collaboration with major international AI companies such as AMD's and NVIDIA鈥檚 southern research centers. This move is intended to facilitate software-hardware integration and field validation, thereby building a complete ecosystem of biomedicine along the southwestern coast.
Chairman Tu emphasized that beyond merely bringing technologies down south, they aim at deeply integrating industrial development capabilities with local resources for co-creating Taiwan鈥檚 new engine in bio-tech industries. He hopes this southern office will connect northern tech parks like Nangang Software Park and Taipei BioPark to create a biotech corridor from north to south.
Interim Executive Director Chen Hsiu-Hui stated that the Biotech Center plans three strategies to enhance South Taiwan's biotechnology industry: first, 'North Water South Flow,' which involves leveraging the center鈥檚 excellent DNA in technology innovation, industrial development and talent cultivation. Second is an AI boost through their drug discovery platform for assisting companies with building AI capabilities while reducing costs and shortening R&D timelines. Thirdly, software-hardware integration will be achieved by connecting to AMD's and NVIDIA's southern research centers.
Looking ahead to 2025, Chairman Tu said the Biotech Center would focus on three key areas: smart precision health, innovative drug development, and international market expansion for biotechnology products. Precision medicine has become a focal point in bio-tech industry growth; future efforts will include AI technology paired with gene testing and biological databases applied to new drugs.
The center plans to strengthen its research capabilities across full human antibody libraries, nanobody technologies, nucleic acid medicines, as well as expanding services that use artificial intelligence for drug development. This is aimed at accelerating the commercialization of new medications while broadening international markets.
This year, they will further promote cooperation among academia-industry-research-medical sectors with several major medical institutions in Taiwan and internationally including Kaohsiung Medical University Hospital, Tzu Chi General Hospital, China Medical University Hospital, Mackay Memorial Hospital, and Taichung Veterans General Hospital. This collaboration aims to expand clinical research and industrial applications while deepening connections between the Taiwanese biotech industry and global biomedical industries.
(Lead image source: TechNews)
Chairman Tu emphasized that beyond merely bringing technologies down south, they aim at deeply integrating industrial development capabilities with local resources for co-creating Taiwan鈥檚 new engine in bio-tech industries. He hopes this southern office will connect northern tech parks like Nangang Software Park and Taipei BioPark to create a biotech corridor from north to south.
Interim Executive Director Chen Hsiu-Hui stated that the Biotech Center plans three strategies to enhance South Taiwan's biotechnology industry: first, 'North Water South Flow,' which involves leveraging the center鈥檚 excellent DNA in technology innovation, industrial development and talent cultivation. Second is an AI boost through their drug discovery platform for assisting companies with building AI capabilities while reducing costs and shortening R&D timelines. Thirdly, software-hardware integration will be achieved by connecting to AMD's and NVIDIA's southern research centers.
Looking ahead to 2025, Chairman Tu said the Biotech Center would focus on three key areas: smart precision health, innovative drug development, and international market expansion for biotechnology products. Precision medicine has become a focal point in bio-tech industry growth; future efforts will include AI technology paired with gene testing and biological databases applied to new drugs.
The center plans to strengthen its research capabilities across full human antibody libraries, nanobody technologies, nucleic acid medicines, as well as expanding services that use artificial intelligence for drug development. This is aimed at accelerating the commercialization of new medications while broadening international markets.
This year, they will further promote cooperation among academia-industry-research-medical sectors with several major medical institutions in Taiwan and internationally including Kaohsiung Medical University Hospital, Tzu Chi General Hospital, China Medical University Hospital, Mackay Memorial Hospital, and Taichung Veterans General Hospital. This collaboration aims to expand clinical research and industrial applications while deepening connections between the Taiwanese biotech industry and global biomedical industries.
(Lead image source: TechNews)